Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) is a global leader in innovative eye care solutions, specializing in visioncare products and ophthalmic surgical equipment. This page aggregates official company announcements, financial disclosures, and strategic developments for stakeholders tracking its market position.
Access real-time updates on product innovations, regulatory milestones, and financial performance. Investors and industry professionals will find curated press releases covering earnings reports, partnership announcements, and clinical trial outcomes.
Key content includes updates on contact lens technologies, intraocular lens advancements, and surgical system innovations. All materials are sourced directly from Alcon's communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to Alcon's latest developments. Combine this resource with SEC filings and market analysis tools for comprehensive investment research.
Alcon (NYSE:ALC) reported Q3 2025 sales of $2.6B, up 6% reported (5% cc), with diluted EPS of $0.48 and core diluted EPS of $0.79. Equipment sales accelerated, led by Unity VCS, while PanOptix Pro and Tryptyr showed early traction. Vision Care grew 7% (contact lenses +6%, ocular health +7%).
Cash from operations was $1.6B and free cash flow $1.2B for the first nine months; the company returned $550M to shareholders. Full-year 2025 guidance was maintained (net sales $10.3–$10.4B; core diluted EPS $3.05–$3.15). The company expects a full-year tariff headwind of about $100M, which it expects to offset through FX and operational actions.
STAAR Surgical (NASDAQ: STAA) and Alcon (NYSE: ALC) agreed amendments to their merger agreement that create a new 30-day go-shop allowing STAAR to solicit third-party proposals through December 6, 2025. Under the amendment, Alcon waives matching rights and limited information rights during the go-shop, and STAAR will not pay a termination fee if it accepts a superior qualified proposal.
The companies said Alcon will engage with STAAR stockholders and proxy advisors. STAAR postponed its Special Meeting to vote on the merger to December 19, 2025 (previously December 3, 2025); stockholders of record as of October 24, 2025 remain entitled to vote.
Yunqi Capital, a 5.1% STAAR Surgical (NASDAQ:STAA) shareholder, praised STAAR’s Q3 2025 results and urged STAAR’s board to terminate the proposed sale to Alcon (SIX/NYSE:ALC). Yunqi highlighted cost discipline: reported operating expenses of $59.4M, excluding $5.9M merger costs an implied run rate of $214M vs prior guidance of $225M. Cash, cash equivalents and investments rose to $192.7M from $189.9M sequentially. Yunqi says China ICL demand recovered, disputes Alcon’s selective use of IQVIA and McKinsey data, and calls Alcon’s $28/share proposal opportunistic. Yunqi notes ~72% of outstanding STAAR shares reportedly voted against the deal as of Oct 23, 2025, and offers to join the board to add shareholder perspective.
Broadwood Partners (investor in STAAR Surgical, NASDAQ:STAA) on Nov 4, 2025 urged shareholders to vote AGAINST Alcon’s (NYSE:ALC) proposed acquisition of STAAR. Broadwood says it owns 27.5% of STAAR and criticizes an Alcon presentation as "fallacious" and misleading, arguing the STAAR board should not delay the shareholder vote or seek Alcon’s permission to run a strategic process. Broadwood cites what it describes as broad shareholder and proxy-advisor opposition to the deal and highlights prior procedural adjournments of STAAR’s Special Meeting. The statement frames the transaction as distracting and harmful to STAAR’s business and directs shareholders to a campaign site for more information.
Company (NYSE:ALC) faced public shareholder resistance after Yunqi Capital, a 5.1% shareholder, sent a letter urging STAAR Surgical’s board to terminate the proposed merger announced Aug 5, 2025.
Yunqi cited a postponed special meeting now set for December 3, 2025, reported vote results showing roughly 72% of outstanding shares opposed the merger and about 81% opposed a $55 million executive compensation package, and said Alcon provided no commitment to increase consideration as of October 24, 2025.
STAAR Surgical (merger with Alcon, ALC) postponed its Special Meeting of Stockholders from November 6, 2025 to December 3, 2025 at 8:30 a.m. PT because of ongoing discussions with Alcon. The new record date for voting eligibility is the close of business on October 24, 2025. Stockholders holding shares as of that record date will be eligible to vote at the postponed meeting, and STAAR will provide a notice and meeting materials in advance. Stockholders with voting questions are instructed to contact STAAR’s proxy solicitor, Innisfree M&A Incorporated, at the provided toll-free and broker phone numbers.
FAQ
What is the current stock price of Alcon (ALC)?
What is the market cap of Alcon (ALC)?
